Recurrent Thyroid CancerNCT06733766
Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer
An observational study of Recurrent Thyroid Cancer, run by Chinese PLA General Hospital at 1 site in China.
Trial summary
To evaluate the long-term outcomes of ultrasound-guided thermal ablation for recurrent thyroid cancer Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Recurrent Thyroid Cancer
- What is being tested?
- ultrasound-guided thermal ablation
- Type of treatment
- Surgery or procedure
- How many people
- 300 participants
- Where
- 1 siteChina
- Study dates
- 9 Dec 2024to 31 Dec 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients with recurrent thyroid cancer
Who may be able to join
- patient received thyroidectomy for thyroid cancer
- recurrent lesions were pathologically proven to be malignant by core-needle biopsy or fine needle aspiration
- no evidence of distant metastases.
- follow-up period ≥12 months
Who cannot join
- coagulation disorder, serious heart, respiratory, liver, or renal failure
- dysfunction of the vocal cord on the opposite side
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853
Lin Yan
Lin Yan
About this study
Official title: Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer: A Multicenter Study
To evaluate the long-term outcomes of ultrasound-guided thermal ablation for recurrent thyroid cancer
Read the detailed description
To evaluate and predict the long-term outcomes of ultrasound-guided thermal ablation for recurrent thyroid cancer by a multicenter study
- Conditions
- Recurrent Thyroid Cancer
- Being tested
- ultrasound-guided thermal ablation
- Medical subject headings
- Thyroid Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ultrasound-guided thermal ablationProcedure or surgery
microwave ablation, radiofrequency ablation, laser ablation
| Study group | Role | What they receive |
|---|---|---|
| ultrasound-guided thermal ablation | ultrasound-guided thermal ablation Receives: Procedure: ultrasound-guided thermal ablation |
What is being measured
The primary outcome is the main question the study is designed to answer.
rate of disease progression
cervical lymph node metastases and persistent tumors confirmed by pathology, Distant metastasis detected by CT, positron emission tomography, or bone scan if there were suspicious symptoms.
Measured: through study completion, an average of 6 months
Secondary outcomes (5)
rate of complications
complication of ablation
Measured: 1 week
rate of volume reduction
volume reduction of tumor after ablation on ultrasound and contrast-enhanced ultrasound
Measured: through study completion, an average of 6 months
rate of tumor disappearance
complete disappearance of ablated tumor on ultrasound and contrast-enhanced ultrasound
Measured: through study completion, an average of 6 months
Tg level
serum thyroglobulin level
Measured: through study completion, an average of 6 months
rate of delayed surgery
patients underwent surgery after ablation because of anxiety
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2024
- Study start9 Dec 2024
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Recurrent Thyroid CancerStudies of the same condition, open and under way.
- More trials run by Chinese PLA General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese PLA General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yu-kun Luo, Chinese PLA General Hospital
- Investigators
- Yukun Luo, Principal investigator, Chinese PLA General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06733766
- Sponsor's protocol ID
- 2024-657
- Status last verified
- Feb 2025
- First submitted
- 7 Dec 2024
- Last updated
- 14 Feb 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer: A Multicenter Study
- ClinicalTrials.gov ID
- NCT06733766
- Acronym / sponsor ID
- 2024-657
- Conditions
- Recurrent Thyroid Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Chinese PLA General HospitalUniversity, hospital or other
- Study start
- 9 Dec 2024 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 13 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the long-term outcomes of ultrasound-guided thermal ablation for recurrent thyroid cancer
Detailed description
To evaluate and predict the long-term outcomes of ultrasound-guided thermal ablation for recurrent thyroid cancer by a multicenter study
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| ultrasound-guided thermal ablation | – | Procedure: ultrasound-guided thermal ablationultrasound-guided thermal ablation |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients with recurrent thyroid cancer
Key inclusion criteria (4 listed)
- patient received thyroidectomy for thyroid cancer
- recurrent lesions were pathologically proven to be malignant by core-needle biopsy or fine needle aspiration
- no evidence of distant metastases.
- follow-up period ≥12 months
Key exclusion criteria (2 listed)
- coagulation disorder, serious heart, respiratory, liver, or renal failure
- dysfunction of the vocal cord on the opposite side
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ultrasound-guided thermal ablationmicrowave ablation, radiofrequency ablation, laser ablation | Procedure or surgery | ultrasound-guided thermal ablation |
Primary outcome
rate of disease progression
Time frame: through study completion, an average of 6 months
cervical lymph node metastases and persistent tumors confirmed by pathology, Distant metastasis detected by CT, positron emission tomography, or bone scan if there were suspicious symptoms.
5 secondary outcomes
rate of complications
Time frame: 1 week
rate of volume reduction
Time frame: through study completion, an average of 6 months
rate of tumor disappearance
Time frame: through study completion, an average of 6 months
Tg level
Time frame: through study completion, an average of 6 months
rate of delayed surgery
Time frame: through study completion, an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Feb 2025.
- Individual participant dataSharing planned: No
Related trials for Recurrent Thyroid Cancer
Not yet recruiting
Endotracheal Tube Versus Transcartilage Needle Electrodes for Nerve Monitoring in Thyroid Surgery
Thyroid Diseases, Recurrent Laryngeal Nerve Injury
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Active, not recruitingPhase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Active, not recruitingPhase 2
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma
RecruitingPhase 1/2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Non-small Cell Lung Cancer, Histiocytic Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yukun Luo principal investigator
Chinese PLA General Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Recurrent Thyroid Cancer, run by Chinese PLA General Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lin Yan (13811237313 ext. 86, gemma-y@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
rate of disease progression (time frame: through study completion, an average of 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2025.